Effect of levetiracetam on hippocampal protein expression and cell proliferation in rats

Epilepsy Research

Volumn 90, Issue 1-2, 2010, Pages 110-120

  Paulson, Linda ^a,b   Persson, Åsa ^a   Vonck, Kristl ^c   Van Dycke, Annelies ^c   Kuhn, H Georg ^a   Boon, Paul ^c   Ben Menachem, Elinor ^a   Raedt, Robrecht ^c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Cell proliferation; Epilepsy; Hippocampus; Levetiracetam; Proteomics

Indexed keywords

ALDOLASE 3; ALPHA ENOLASE; ALPHA TROPOMYOSIN; ALPHA TUBULIN 6; BETA 2A TUBULIN; BETA ACTIN; BRAIN PROTEIN; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; CORTACIN; CYTOCHROME C OXIDASE; DISMUTASE; DYNAMIN; ETIRACETAM; GLIAL FIBRILLARY ACIDIC PROTEIN DELTA; HEAT SHOCK PROTEIN 70; MYELIN BASIC PROTEIN; NADH DEHYDROGENASE FLAVOPROTEIN 2; NUCLEOSIDE DIPHOSPHATE KINASE; PEROXIREDOXIN 2; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; SYNAPSIN IB; TRANSGELIN 3; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG; ANTICONVULSIVE AGENT; BROXURIDINE; PIRACETAM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HIPPOCAMPUS; HISTOCHEMISTRY; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; TWO DIMENSIONAL GEL ELECTROPHORESIS; ANALOGS AND DERIVATIVES; ANIMAL; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; MULTIVARIATE ANALYSIS; PRINCIPAL COMPONENT ANALYSIS; PROCEDURES; PROTEIN DATABASE; SPRAGUE DAWLEY RAT; STATISTICS AND NUMERICAL DATA;

ANIMALS; ANTICONVULSANTS; BROMODEOXYURIDINE; CELL PROLIFERATION; DATABASES, PROTEIN; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; GENE EXPRESSION REGULATION; HIPPOCAMPUS; MASS SPECTROMETRY; MULTIVARIATE ANALYSIS; PIRACETAM; PRINCIPAL COMPONENT ANALYSIS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 77953538798     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2010.03.015     Document Type: Article

References (42)

1. 2+ transients and epileptiform potentials in hippocampal neurons. Neuroreport 2003, 14:471-475.
2. Blaya C., Moorjani P., Salum G.A., Goncalves L., Weiss L.A., Leistner-Segal S., Manfro G.G., Smoller J.W. Preliminary evidence of association between EFHC2, a gene implicated in fear recognition, and harm avoidance. Neurosci. Lett. 2009, 452:84-86.
3. Chen J., Cai F., Cao J., Zhang X., Li S. Long-term antiepileptic drug administration during early life inhibits hippocampal neurogenesis in the developing brain. J. Neurosci. Res. 2009, 87:2898-2907.
4. Coggeshall R.E., Lekan H.A. Methods for determining numbers of cells and synapses: a case for more uniform standards of review. J. Comp. Neurol. 1996, 364:6-15.
5. Custer K.L., Austin N.S., Sullivan J.M., Bajjalieh S.M. Synaptic vesicle protein 2 enhances release probability at quiescent synapses. J. Neurosci. 2006, 26:1303-1313.
6. Davidsson P., Paulson L., Hesse C., Blennow K., Nilsson C.L. Proteome studies of human cerebrospinal fluid and brain tissue using a preparative two-dimensional electrophoresis approach prior to mass spectrometry. Proteomics 2001, 1:444-452.
7. De Smedt T., Raedt R., Vonck K., Boon P. Levetiracetam. Part II. The clinical profile of a novel anticonvulsant drug. CNS Drug Rev. 2007, 13:57-78.
8. Eriksson E., Johansson E., Kettaneh-Wold N., Wold S. Multi- and megavariate data analysis 2006, Umetrics AB.
9. Feys P., D'hooghe M.B., Nagels G., Helsen W.F. The effect of levetiracetam on tremor severity and functionality in patients with multiple sclerosis. Mult. Scler. 2009, 15:371-378.
10. Fuks B., Gillard M., Michel P., Lynch B., Vertongen P., Leprince P., Klitgaard H., Chatelain P. Localization and photoaffinity labelling of the levetiracetam binding site in rat brain and certain cell lines. Eur. J. Pharmacol. 2003, 478:11-19.
11. Gillard M., Fuks B., Michel P., Vertongen P., Massingham R., Chatelain P. Binding characteristics of [3H]ucb 30889 to levetiracetam binding sites in rat brain. Eur. J. Pharmacol. 2003, 478:1-9.
12. Gower A.J., Noyer M., Verloes R., Gobert J., Wulfert E. ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur. J. Pharmacol. 1992, 222:193-203.
13. Gu J., Lynch B.A., Anderson D., Klitgaard H., Lu S., Elashoff M., Ebert U., Potschka H., Loscher W. The antiepileptic drug levetiracetam selectively modifies kindling-induced alterations in gene expression in the temporal lobe of rats. Eur. J. Neurosci. 2004, 19:334-345.
14. Gundersen H.J., Bendtsen T.F., Korbo L., Marcussen N., Moller A., Nielsen K., Nyengaard J.R., Pakkenberg B., Sorensen F.B., Vesterby A. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS 1988, 96:379-394.
15. Hao Y., Creson T., Zhang L., Li P., Du F., Yuan P., Gould T.D., Manji H.K., Chen G. Mood stabilizer valproate promotes erk pathway-dependent cortical neuronal growth and neurogenesis. J. Neurosci. 2004, 24:6590-6599.
16. Helmstaedter C., Fritz N.E., Kockelmann E., Kosanetzky N., Elger C.E. Positive and negative psychotropic effects of levetiracetam. Epilepsy Behav. 2008, 13:535-541.
17. Jakubs K., Nanobashvili A., Bonde S., Ekdahl C.T., Kokaia Z., Kokaia M., Lindvall O. Environment matters: synaptic properties of neurons born in the epileptic adult brain develop to reduce excitability. Neuron 2006, 52:1047-1059.
18. Jessberger S., Nakashima K., Clemenson G.D., Mejia E., Mathews E., Ure K., Ogawa S., Sinton C.M., Gage F.H., Hsieh J. Epigenetic modulation of seizure-induced neurogenesis and cognitive decline. J. Neurosci. 2007, 27:5967-5975.
19. Klitgaard H. Levetiracetam: the preclinical profile of a new class of antiepileptic drugs?. Epilepsia 2001, 42:13-18.
20. Lee C.H., Lee C.Y., Tsai T.S., Liou H.H. PKA-mediated phosphorylation is a novel mechanism for levetiracetam, an antiepileptic drug, activating ROMK1 channels. Biochem. Pharmacol. 2008, 76:225-235.
21. Loscher W., Honack D., Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J. Pharmacol. Exp. Ther. 1998, 284:474-479.
22. Lukyanetz E.A., Shkryl V.M., Kostyuk P.G. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 2002, 43:9-18.
23. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. PNAS 2004, 101:9861-9866.
24. Madeja M., Margineanu D.G., Gorji A., Siep E., Boerrigter P., Klitgaard H., Speckmann E.J. Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action?. Neuropharmacology 2003, 45:661-671.
25. Margineanu D.G., Klitgaard H. Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. Pharmacol. Res. 2000, 42:281-285.
26. Nagarkatti N., Deshpande L.S., DeLorenzo R.J. Levetiracetam inhibits both ryanodine and IP3 receptor activated calcium induced calcium release in hippocampal neurons in culture. Neurosci. Lett. 2008, 436:289-293.
27. Niespodziany I., Klitgaard H., Margineanu D.G. Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slices. Neurosci. Lett. 2001, 306:5-8.
28. Noyer M., Gillard M., Matagne A., Henichart J.P., Wulfert E. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur. J. Pharmacol. 1995, 286:137-146.
29. Palma E., Roseti C., Maiolino F., Fucile S., Martinello K., Mazzuferi M., Aronica E., Manfredi M., Esposito V., Cantore G., Miledi R., Simonato M., Eusebi F. GABA(A)-current rundown of temporal lobe epilepsy is associated with repetitive activation of GABA(A) " phasic" receptors. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:20944-20948.
30. Parent J.M., Elliott R.C., Pleasure S.J., Barbaro N.M., Lowenstein D.H. Aberrant seizure-induced neurogenesis in experimental temporal lobe epilepsy. Ann. Neurol. 2006, 59:81-91.
31. Parent J.M., Lowenstein D.H. Seizure-induced neurogenesis: are more new neurons good for an adult brain?. Prog. Brain Res. 2002, 135:121-131.
32. Parent J.M., Yu T.W., Leibowitz R.T., Geschwind D.H., Sloviter R.S., Lowenstein D.H. Dentate granule cell neurogenesis is increased by seizures and contributes to aberrant network reorganization in the adult rat hippocampus. J. Neurosci. 1997, 17:3727-3738.
33. Pierce J.P., Melton J., Punsoni M., McCloskey D.P., Scharfman H.E. Mossy fibers are the primary source of afferent input to ectopic granule cells that are born after pilocarpine-induced seizures. Exp. Neurol. 2005, 196:316-331.
34. Raedt R., Van Dycke A., Boterberg T., Alborn A.M., De Smedt T., Wyckhuys T., De Herdt V., Waterschoot L., Vonck K., Peter E., Ben-Menachem E., Boon P. Low-dose whole brain gamma-irradiation accelerates epileptogenesis during hippocampal kindling. Epilepsia 2006, 47:232-233.
35. Shapiro L.A., Korn M.J., Ribak C.E. Newly generated dentate granule cells from epileptic rats exhibit elongated hilar basal dendrites that align along GFAP-immunolabeled processes. Neuroscience 2005, 136:823-831.
36. Shapiro L.A., Ribak C.E. Integration of newly born dentate granule cells into adult brains: hypotheses based on normal and epileptic rodents. Brain Res. Brain Res. Rev. 2005, 48:43-56.
37. Shapiro L.A., Ribak C.E. Newly born dentate granule neurons after pilocarpine-induced epilepsy have hilar basal dendrites with immature synapses. Epilepsy Res. 2006, 69:53-66.
38. Shin S.Y., Rath O., Choo S.M., Fee F., McFerran B., Kolch W., Cho K.H. Positive- and negative-feedback regulations coordinate the dynamic behavior of the Ras-Raf-MEK-ERK signal transduction pathway. J. Cell Sci. 2009, 122:425-435.
39. Silver J.M., Shin C., McNamara J.O. Antiepileptogenic effects of conventional anticonvulsants in the kindling model of epilespy. Ann. Neurol. 1991, 29:356-363.
40. Stratton S.C., Large C.H., Cox B., Davies G., Hagan R.M. Effects of lamotrigine and levetiracetam on seizure development in a rat amygdala kindling model. Epilepsy Res. 2003, 53:95-106.
41. Trygg J., Wold S. Orthogonal projection to latent structures (O-PLS). J. Chemom. 2002, 16:119-128.
42. Wada J.A., Wake A., Sato M., Corcoran M.E. Antiepileptic and prophylactic effects of tetrahydrocannabinols in amygdaloid kindled cats. Epilepsia 1975, 16:503-510.